- Datum28.10.2025
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Ingmar Königshofen
Moderator
Verrica Pharmaceuticals Inc. Aktie
Verkaufen
Kaufen
Verrica Pharmaceuticals Inc. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Verrica Pharmaceuticals Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-3,22 %
Intraday
-7,57 %
1 Woche
-9,28 %
1 Monat
-44,14 %
Seit Jahresbeginn
-74,11 %
1 Jahr
-83,71 %
3 Jahre
-95,39 %
5 Jahre
Passender Service zu Verrica Pharmaceuticals Inc.
Webinar zu Verrica Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,800-17,382
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Verrica Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Verrica Pharmaceuticals Inc.
Keine aktuellen Termine
Beschreibung
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
